Company: BLCO
Filing Date: 2025-07-30
Form Type: 10-Q
Source: 0001860742-25-000018
Chunk: 117

Company: Bausch & Lomb Corp
Filing Date: 2025-07-30
Form: 10-Q
Item: Item 2
Chunk 117
---
 our audited Consolidated Financial Statements for the year ended December 31, 2024, included in our Annual Report, for further details regarding certain of these infringement proceedings.The risks of generic competition are a fact of the eye health industry and are not specific to our operations or product portfolio. These risks are not avoidable, but we believe they are manageable. To manage these risks, our leadership team routinely evaluates the impact that generic competition may have on future profitability and operations. In addition to aggressively defending our patents and other intellectual property, our leadership team makes operational and investment decisions regarding these products and businesses at risk, including decisions regarding our pipeline. Our leadership team actively manages our pipeline in order to identify innovative and realizable projects that are expected to provide incremental and sustainable revenues and growth into the future. We believe that we have a well-established product portfolio that is diversified within our core businesses. We also believe that we have a robust pipeline that not only provides for the next generation of our existing products, but also brings new solutions into the market.See the section entitled “Risk Factors” included in our Annual Report, for additional information on the risks associated with our intellectual property and our competition risks.

37

RESULTS OF OPERATIONSOur unaudited operating results for the three and six months ended June 30, 2025 and 2024 were as follows:Three Months EndedJune 30,Six Months EndedJune 30,(in millions)20252024Change20252024ChangeRevenuesProduct sales$1,272 $1,213 $59 $2,405 $2,307 $98 Other revenues6 3 3 10 8 2 1,278 1,216 62 2,415 2,315 100 ExpensesCost of goods sold (excluding amortization and impairments of intangible assets)523 482 41 1,004 905 99 Cost of other revenues2 1 1 3 2 1 Selling, general and administrative (Note 4)579 535 44 1,142 1,039 103 Research and development96 84 12 182 166 16 Amortization of intangible assets67 74 (7)134 148 (14)Other expense, net22 14 8 44 23 21 1,289 1,190 99 2,509 2,283 226 Operating (loss